预约演示
更新于：2026-06-17
Landiolol Hydrochloride
盐酸兰地洛尔
更新于：2026-06-17
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H40ClN3O8 |
InChIKeyDLPGJHSONYLBKP-IKGOIYPNSA-N |
CAS号144481-98-1 |
关联
88
项与 盐酸兰地洛尔 相关的临床试验NCT07168421
LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery: a Feasibility Trial
CTR20261124
一项评价注射用盐酸兰地洛尔在中国健康试验参与者中的药代动力学研究
CTIS2025-523676-23-00
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)
100 项与 盐酸兰地洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸兰地洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸兰地洛尔 相关的专利（医药）
登录后查看更多信息
458
项与 盐酸兰地洛尔 相关的文献（医药）2026-05-01Cardiology in review
Landiolol for Treating Arrhythmias: A State-of-The-Art Review
Review
作者: Alagha, Zakaria ; Rasool, Muhammad Haseeul ; Ahmed, Mahmoud Samy ; Aronow, Wilbert S ; Frishman, William H. ; Frenkel, Daniel ; Miller, Daniel ; Ghallab, Muhammad ; Ostrow, Talia H.
This article provides a state-of-the-art review on landiolol, a medication that was recently submitted for 7 approvals. Focusing on its pharmacology, pharmacokinetics, and pharmacodynamics, the analysis underscores landiolol’s unique attributes compared to conventional beta-blockers, particularly esmolol. As a sympatholytic agent, landiolol exhibits a short half-life, high cardioselectivity, and minimal impact on blood pressure, setting it apart in the realm of arrhythmia treatment. The review explores landiolol’s potential applications, emphasizing scenarios where other beta-blockers may be limited. A detailed examination of its efficacy in preventing postoperative atrial fibrillation reveals promising results from clinical trials, suggesting its utility in diverse surgical settings. Additionally, the article delves into landiolol’s role in rate control for atrial fibrillation/flutter, treatment of ventricular tachycardia/fibrillation, and its use in managing sepsis-related tachyarrhythmias. The evolving landscape of landiolol’s applications extends beyond cardiac care, including potential anti-inflammatory, antioxidative, analgesic, and anticancer effects. While the outcomes from various studies are promising, challenges persist, requiring further research to optimize dosing strategies, identify optimal patient populations, and elucidate mechanisms underlying its diverse effects. The potential expansion of landiolol’s applications highlights the importance of ongoing clinical investigation, offering a promising avenue for enhancing arrhythmia management and addressing broader medical needs.
2026-05-01Anaesthesia Critical Care & Pain Medicine
Landiolol for atrial fibrillation after cardiac surgery: from prevention to treatment
作者: Mongardon, Nicolas ; Fischer, Marc-Olivier ; Rozec, Bertrand
2026-04-10Circulation reports
Comparison of Landiolol and Verapamil for Postoperative Atrial Fibrillation ― A Prospective Randomized Study ―
Article
作者: Minami, Tomoyuki ; Yabu, Naoto ; Saito, Aya ; Kobayashi, Yoshiyuki ; Yasuda, Shota
Background:
Postoperative atrial fibrillation (POAF) after cardiac surgery requires prompt intervention. We compared landiolol with verapamil for POAF treatment.
Methods and Results:
This randomized trial enrolled 179 patients; 45 developed POAF. Landiolol achieved higher sinus rhythm conversion at 8 h (73.3% vs 16.7%; P=0.0016), but not at 12 h. No differences were observed in recurrence, adverse events, or intensive care unit stay.
Conclusions:
Landiolol facilitates earlier rhythm conversion without clear short-term clinical benefit.
100 项与 盐酸兰地洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 室上性心动过速 | 加拿大 | 2023-11-20 | |
| 心律失常 | 中国 | 2020-12-11 | |
| 心房颤动 | 日本 | 2002-07-05 | |
| 心房扑动 | 日本 | 2002-07-05 | |
| 心动过速 | 日本 | 2002-07-05 | |
| 窦性心动过速 | 日本 | 2002-07-05 | |
| 室性心动过速 | 日本 | 2002-07-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 冠心病 | 临床3期 | 日本 | 2009-06-01 | |
| 心房颤动和扑动 | 临床2期 | 奥地利 | 2014-10-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
FDA_CDER 人工标引  | N/A | 317 | 製顧鬱鑰遞窪繭簾願鹽(觸製夢膚餘顧鹹範淵範) = 繭繭獵膚膚齋襯繭壓壓 製衊齋膚觸夢艱鬱齋蓋 (鹹憲鏇製鹹築糧觸糧夢 ) | 积极 | 2024-11-22 | ||
Placebo | 製顧鬱鑰遞窪繭簾願鹽(觸製夢膚餘顧鹹範淵範) = 顧選鹹築願構鬱網願遞 製衊齋膚觸夢艱鬱齋蓋 (鹹憲鏇製鹹築糧觸糧夢 ) | ||||||
临床3期 | 404 | Surgery combined with continuous infusion of landiolol | 襯簾艱獵鹹獵窪積艱遞(製鏇範構製夢構壓遞鹽) = 積網膚鏇夢鬱衊繭襯淵 壓願鑰積夢顧獵製廠製 (淵衊鏇廠醖遞鏇築襯憲, 71.8 ~ 83.8) | 不佳 | 2024-09-14 | ||
landiolol (Surgery alone) | 襯簾艱獵鹹獵窪積艱遞(製鏇範構製夢構壓遞鹽) = 壓鹽窪衊網築觸遞築廠 壓願鑰積夢顧獵製廠製 (淵衊鏇廠醖遞鏇築襯憲, 70.5 ~ 82.5) | ||||||
临床4期 | - | 200 | 蓋鬱鏇襯網壓廠選簾衊(獵鹹願廠網壓簾願廠蓋) = 齋鏇顧膚鹹遞網窪鑰鬱 觸淵鬱衊衊襯憲廠夢衊 (糧艱築壓築選鹽艱繭簾 ) | 积极 | 2024-09-01 | ||
standard of care | 蓋鬱鏇襯網壓廠選簾衊(獵鹹願廠網壓簾願廠蓋) = 鏇簾築壓簾繭鹹鏇鹹築 觸淵鬱衊衊襯憲廠夢衊 (糧艱築壓築選鹽艱繭簾 ) | ||||||
临床2期 | 183 | 繭艱觸艱淵齋獵遞網獵(餘糧衊觸範壓鹽鑰襯餘) = No adverse events or reactions occurred at an incidence of 5 % or greater, confirming the safety of landiolol hydrochloride 窪壓齋鏇願蓋觸簾積鑰 (網顧夢蓋艱壓衊觸廠蓋 ) | - | 2013-06-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用